Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial

PURPOSE: Hemophilia care in China is characterized by widespread use of on-demand regimens and low-dose prophylaxis. With a limited number of approved recombinant factor VIII (FVIII) products, the incidence of arthropathy and disability in hemophilia patients remains high in China. The purpose of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Runhui, Sun, Jing, Xu, Weiqun, Hu, Qun, Li, Wenqian, Xiao, Jianwen, Yang, Feng’e, Zeng, Xiaojing, Zeng, Yun, Zhou, Jianfeng, Matytsina, Irina, Zhang, Sali, Pluta, Michael, Yang, Renchi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320881/
https://www.ncbi.nlm.nih.gov/pubmed/32606716
http://dx.doi.org/10.2147/TCRM.S243146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320881/
https://www.ncbi.nlm.nih.gov/pubmed/32606716
http://dx.doi.org/10.2147/TCRM.S243146

Ejemplares similares